Document is current
Any future updates will be listed below
-
Authors
Morey, Trevor M.
Benatar, Tania
Xu, Stacey X.
Wang, Ling
Ip, Philbert
Nitya-Nootan, Thanyashanthi
Thakor, Gargi
Bader, Andreas G.
Helsen, Christopher W.
Houry, Walid A.
-
Funding
Funding for this research was provided by:
Mitacs (IT23589 and IT37046)
Canadian Institutes of Health Research (PJT-173491)
- License Information
-
More Information
Article History
Received: 9 October 2024
Accepted: 23 January 2025
First Online: 25 February 2025
Declarations
:
: This work has been funded in part by Triumvira Immunologics, a for-profit biotechnology R&D company and current developer and shared patent-holder of the TAC receptor technology (patents #US11110123B2 and #US10435453B2). Authors T.B., S.X.X., L.W., P.I., T.N.N., G.T., A.G.B., and C.W.H. were employed by Triumvira Immunologics during completion of this study. Authors T.M.M. and W.A.H. declare no financial or competing interests.
